RESULTS FROM WORK TO DEVELOP A PARSORTIX-BASED Her2 assay KIT SHOWCASED AT INTERNATIONAL LIQUID BIOPSY CONFERENCE ...

Treatment for breast cancer can come in many forms. In addition to surgery to remove cancerous tissue and radiation therapy, ...

SYNC, its first homegrown CAR-T therapy, one of the first to show promise in treating certain types of brain cancers. This ...

Barbara O’Brien, MD, discussed findings and implications from the phase 2 TBCRC049 study evaluating the combination of ...

Researchers from the George Washington University and the Washington DC Veterans Affairs Medical Center have published a case ...

2:02 | So, 66% in terms of an intracranial response rate is very high and really the highest that we have ever seen for an ...

Medicaid expansion was associated with a slower decrease in receipt of guideline-concordant treatment, reduced delays in treatment initiation, and improved 2-year survival, according to researchers.

Cite this: The Role of Hormonal Therapy in the Management of Hormonal-Receptor-Positive Breast Cancer With Co-Expression of HER2 - Medscape - Sep 01, 2008. The article is based primarily on a ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Friday.

An early-stage HER2-positive (HER2+) breast cancer is always a shock, but today’s treatment options should give you hope. Over the past 2 decades, advances in medicine have brought us new ...